Candel Therapeutics CADL
NASDAQ CADL
$10.79 -0.09 (-0.83%)
As of: Sep 30, 2026 · 12:43 PM EDT

Candel Therapeutics, Inc. (CADL) EBITDA Margin (2020 - 2022)

Updated

Candel Therapeutics' EBITDA Margin came in at -25558.06% for Q4 2022, down 1164.52 percentage points from -24393.55% a year earlier but up 2445.16 percentage points from the prior quarter.

Analysis

Candel Therapeutics, Inc. (CADL) EBITDA Margin (2020 - 2022) Analysis & Trends

For FY2022, Candel Therapeutics' EBITDA Margin was -27155.20%, down 6760.00 percentage points from FY2021.

  • Going back by year, EBITDA Margin was -20395.20% in FY2021 (-9420.00 pp) and -10975.20% in FY2020.
  • The five-year range for quarterly EBITDA Margin is -28454.84% (Q1 2022) to -8722.58% (Q3 2020).
  • Year-over-year, EBITDA Margin has declined for six consecutive quarters, with an average year-over-year change of -8195.16 percentage points over the last six quarters.
  • Business Quant data shows CADL's EBITDA Margin at -28003.23% (Q3 2022), -27632.26% (Q2 2022) and -28454.84% (Q1 2022) in the three quarters before Q4 2022.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -25,558.06%
Sep 30, 2022 -28,003.23%
Jun 30, 2022 -27,632.26%
Mar 31, 2022 -28,454.84%
Dec 31, 2021 -24,393.55%
Sep 30, 2021 -25,832.26%
Jun 30, 2021 -17,077.42%
Mar 31, 2021 -14,938.71%
Dec 31, 2020 -19,738.71%
Sep 30, 2020 -8,722.58%
API Access

Candel Therapeutics, Inc. EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CADL&period=max&api_key=YOUR_API_KEY